This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gottlieb, S. S. Articles by Liittschwager, E. B. Search for Related Content PubMed PubMed Citation Articles by Gottlieb, S. S. Articles by Liittschwager, E. B.

CLINICAL STUDIES

Effects of BG9719 (CVT-124), an A₁-Adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure

Stephen S. Gottlieb, MD, FACC^*, Sandra L. Skettino, MD, Andrew Wolff, MD, Evan Beckman, MD, Michael L. Fisher, MD, FACC^*, Ronald Freudenberger, MD, FACC^*, Tim Gladwell, PharmD^*, Joanne Marshall, RN^*, Michelle Cines, RN^*, Donald Bennett, PhD and Elizabeth B. Liittschwager, BA

^* Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA and the D.V.A. Medical Center, Baltimore, Maryland
CV Therapeutics, Palo Alto, California, USA
Biogen, Cambridge, Massachusetts, USA

Manuscript received December 31, 1998; revised manuscript received July 29, 1999, accepted October 5, 1999.

Reprint requests and correspondence: Dr. Stephen S. Gottlieb, Division of Cardiology, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, Maryland 21201
sgottlie{at}medicine.umaryland.edu

OBJECTIVES

To determine the effects of furosemide and the selective A₁ adenosine receptor BG9719 on renal function in patients with congestive heart failure (CHF).

BACKGROUND

Studies suggest that adenosine may affect renal function by various mechanisms, but the effects of blockade of this system in humans is unknown. In addition, the effects of a therapeutic dose of furosemide on glomerular filtration rate (GFR) and renal plasma flow (RPF) in heart failure patients are controversial.

METHODS

On different days, 12 patients received placebo, BG9719 and furosemide. Glomerular filtration rate, RPF and sodium and water excretion were assessed immediately following drug administration.

RESULTS

Glomerular filtration rate was 84 ± 23 ml/min/1.73m² after receiving placebo, 82 ± 24 following BG9719 administration and a decreased (p < 0.005) 63 ± 18 following furosemide. Renal plasma flow was unchanged at 293 ± 124 ml/min/1.73m² on placebo, 334 ± 155 after receiving BG9719 and 374 ± 231 after receiving furosemide. Sodium excretion increased from 8 ± 8 mEq following placebo administration to 37 ± 26 mEq following BG9719 administration. In the six patients in whom it was measured, sodium excretion was 104 ± 78 mEq following furosemide administration.

CONCLUSIONS

Natriuresis is effectively induced by both furosemide and the adenosine A₁ antagonist BG9719 in patients with CHF. Doses of the two drugs used in this study did not cause equivalent sodium and water excretion but only furosemide decreased GFR. These data suggest that adenosine is an important determinant of renal function in patients with heart failure.

Abbreviations and Acronyms   CHF = congestive heart failure   GFR = glomerular filtration rate   RPF = renal plasma flow

This article has been cited by other articles:

				M. M. Givertz Adenosine A1 Receptor Antagonists at a Fork in the Road Circ Heart Fail, November 1, 2009; 2(6): 519 - 522. [Full Text] [PDF]

				V. Mitrovic, P. Seferovic, S. Dodic, M. Krotin, A. Neskovic, K. Dickstein, H. de Voogd, C. Bocker, D. Ziegler, M. Godes, et al. Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure Circ Heart Fail, November 1, 2009; 2(6): 523 - 531. [Abstract] [Full Text] [PDF]

				A Kazory and E A Ross Ultrafiltration for decompensated heart failure: renal implications Heart, July 1, 2009; 95(13): 1047 - 1051. [Abstract] [Full Text] [PDF]

				A. Kulick, C. Panico, P. Gill, and W. J. Welch Low salt intake increases adenosine type 1 receptor expression and function in the rat proximal tubule Am J Physiol Renal Physiol, July 1, 2008; 295(1): F37 - F41. [Abstract] [Full Text] [PDF]

				V. Vallon, C. Miracle, and S. Thomson Adenosine and kidney function: Potential implications in patients with heart failure Eur J Heart Fail, February 1, 2008; 10(2): 176 - 187. [Abstract] [Full Text] [PDF]

				L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes Eur J Heart Fail, February 1, 2008; 10(2): 201 - 213. [Abstract] [Full Text] [PDF]

				B. Greenberg, I. Thomas, D. Banish, S. Goldman, E. Havranek, B. M. Massie, Y. Zhu, B. Ticho, and W. T. Abraham Effects of Multiple Oral Doses of an A1 Adenosine Antagonist, BG9928, in Patients With Heart Failure: Results of a Placebo-Controlled, Dose-Escalation Study J. Am. Coll. Cardiol., August 14, 2007; 50(7): 600 - 606. [Abstract] [Full Text] [PDF]

				E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409. [Abstract] [Full Text] [PDF]

				F. Zannad, A. Mebazaa, Y. Juilliere, A. Cohen-Solal, L. Guize, F. Alla, P. Rouge, P. Blin, M.-H. Barlet, L. Paolozzi, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study Eur J Heart Fail, November 1, 2006; 8(7): 697 - 705. [Abstract] [Full Text] [PDF]

				V. Vallon, B. Muhlbauer, and H. Osswald Adenosine and kidney function. Physiol Rev, July 1, 2006; 86(3): 901 - 940. [Abstract] [Full Text] [PDF]

				R. D. Brown, P. Thoren, A. Steege, R. Mrowka, J. Sallstrom, O. Skott, B. B. Fredholm, and A. E. G. Persson Influence of the adenosine A1 receptor on blood pressure regulation and renin release Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2006; 290(5): R1324 - R1329. [Abstract] [Full Text] [PDF]

				D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, K. Rao, et al. Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine Circulation, September 21, 2004; 110(12): 1620 - 1625. [Abstract] [Full Text] [PDF]

				J. A. Auchampach, X. Jin, J. Moore, T. C. Wan, L. M. Kreckler, Z.-D. Ge, J. Narayanan, E. Whalley, W. Kiesman, B. Ticho, et al. Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 846 - 856. [Abstract] [Full Text] [PDF]

				K. H Chee, K. Amudha, N. A Hussain, H. K Haizal, A.-M. J Choy, and C. C Lang Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 140 - 148. [Abstract] [PDF]

				J J V McMurray Heart failure in 10 years time: focus on pharmacological treatment Heart, October 1, 2002; 88(90002): ii40 - 46. [Full Text] [PDF]

				E. K. Jackson, C. Zhu, and S. P. Tofovic Expression of adenosine receptors in the preglomerular microcirculation Am J Physiol Renal Physiol, July 1, 2002; 283(1): F41 - F51. [Abstract] [Full Text] [PDF]

				M. C. Montesinos, A. Desai, J.-F. Chen, H. Yee, M. A. Schwarzschild, J. S. Fink, and B. N. Cronstein Adenosine Promotes Wound Healing and Mediates Angiogenesis in Response to Tissue Injury Via Occupancy of A2A Receptors Am. J. Pathol., June 1, 2002; 160(6): 2009 - 2018. [Abstract] [Full Text] [PDF]

				J. McMurray and M. A. Pfeffer New Therapeutic Options in Congestive Heart Failure: Part I Circulation, April 30, 2002; 105(17): 2099 - 2106. [Full Text] [PDF]

				S. S. Gottlieb, D. C. Brater, I. Thomas, E. Havranek, R. Bourge, S. Goldman, F. Dyer, M. Gomez, D. Bennett, B. Ticho, et al. BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy Circulation, March 19, 2002; 105(11): 1348 - 1353. [Abstract] [Full Text] [PDF]

				L. M. Ruilope, D. J. van Veldhuisen, E. Ritz, and T. F. Luscher Renal function: the Cinderella of cardiovascular risk profile J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1782 - 1787. [Abstract] [Full Text] [PDF]

				E. K. Jackson, C. K. Kost Jr., W. A. Herzer, G. J. Smits, and S. P. Tofovic A1 Receptor Blockade Induces Natriuresis with a Favorable Renal Hemodynamic Profile in SHHF/Mcc-facp Rats Chronically Treated with Salt and Furosemide J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 978 - 987. [Abstract] [Full Text] [PDF]

				E. K. Jackson and R. K. Dubey Role of the extracellular cAMP-adenosine pathway in renal physiology Am J Physiol Renal Physiol, October 1, 2001; 281(4): F597 - F612. [Abstract] [Full Text] [PDF]

				J. Al Suwaidi, P. B. Berger, and D. R. Holmes Jr Coronary Artery Stents JAMA, October 11, 2000; 284(14): 1828 - 1836. [Abstract] [Full Text] [PDF]